These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 39018923)
1. Farnesyl pyrophosphate synthase inhibitors with antiosteoporosis efficacy in ovariectomized rats: A mixed binding approach beyond bisphosphonates. El-Sayed NF; El-Hussieny M; Mansour ST; Fouad MA; Saad MA; Ewies EF Eur J Med Chem; 2024 Oct; 276():116679. PubMed ID: 39018923 [TBL] [Abstract][Full Text] [Related]
2. Novel bisphosphonates with antiresorptive effect in bone mineralization and osteoclastogenesis. Savino S; Toscano A; Purgatorio R; Profilo E; Laghezza A; Tortorella P; Angelelli M; Cellamare S; Scala R; Tricarico D; Marobbio CMT; Perna F; Vitale P; Agamennone M; Dimiccoli V; Tolomeo A; Scilimati A Eur J Med Chem; 2018 Oct; 158():184-200. PubMed ID: 30216851 [TBL] [Abstract][Full Text] [Related]
3. Design of potent bisphosphonate inhibitors of the human farnesyl pyrophosphate synthase via targeted interactions with the active site 'capping' phenyls. De Schutter JW; Shaw J; Lin YS; Tsantrizos YS Bioorg Med Chem; 2012 Sep; 20(18):5583-91. PubMed ID: 22884353 [TBL] [Abstract][Full Text] [Related]
4. Thienopyrimidine bisphosphonate (ThPBP) inhibitors of the human farnesyl pyrophosphate synthase: optimization and characterization of the mode of inhibition. Leung CY; Park J; De Schutter JW; Sebag M; Berghuis AM; Tsantrizos YS J Med Chem; 2013 Oct; 56(20):7939-50. PubMed ID: 23998921 [TBL] [Abstract][Full Text] [Related]
5. Novel bisphosphonate inhibitors of the human farnesyl pyrophosphate synthase. De Schutter JW; Zaretsky S; Welbourn S; Pause A; Tsantrizos YS Bioorg Med Chem Lett; 2010 Oct; 20(19):5781-6. PubMed ID: 20801032 [TBL] [Abstract][Full Text] [Related]
6. Structure of human farnesyl pyrophosphate synthase in complex with an aminopyridine bisphosphonate and two molecules of inorganic phosphate. Park J; Lin YS; Tsantrizos YS; Berghuis AM Acta Crystallogr F Struct Biol Commun; 2014 Mar; 70(Pt 3):299-304. PubMed ID: 24598914 [TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of a series of aromatic bisphosphonates. Barney RJ; Wasko BM; Dudakovic A; Hohl RJ; Wiemer DF Bioorg Med Chem; 2010 Oct; 18(20):7212-20. PubMed ID: 20832326 [TBL] [Abstract][Full Text] [Related]
9. Probing the molecular and structural elements of ligands binding to the active site versus an allosteric pocket of the human farnesyl pyrophosphate synthase. Gritzalis D; Park J; Chiu W; Cho H; Lin YS; De Schutter JW; Lacbay CM; Zielinski M; Berghuis AM; Tsantrizos YS Bioorg Med Chem Lett; 2015 Mar; 25(5):1117-23. PubMed ID: 25630225 [TBL] [Abstract][Full Text] [Related]
10. Multistage screening reveals chameleon ligands of the human farnesyl pyrophosphate synthase: implications to drug discovery for neurodegenerative diseases. De Schutter JW; Park J; Leung CY; Gormley P; Lin YS; Hu Z; Berghuis AM; Poirier J; Tsantrizos YS J Med Chem; 2014 Jul; 57(13):5764-76. PubMed ID: 24911527 [TBL] [Abstract][Full Text] [Related]
11. Mechanistic insights into protonation state as a critical factor in hFPPS enzyme inhibition. Fernández D; Ortega-Castro J; Mariño L; Perelló J; Frau J J Comput Aided Mol Des; 2015 Jul; 29(7):667-80. PubMed ID: 26081258 [TBL] [Abstract][Full Text] [Related]
12. Approaches for Designing new Potent Inhibitors of Farnesyl Pyrophosphate Synthase. Rodriguez JB; Falcone BN; Szajnman SH Expert Opin Drug Discov; 2016; 11(3):307-20. PubMed ID: 26781029 [TBL] [Abstract][Full Text] [Related]
13. Structure-based virtual screening and biological evaluation of novel non-bisphosphonate farnesyl pyrophosphate synthase inhibitors. Liu Q; Miao Y; Wang X; Lv G; Peng Y; Li K; Li M; Qiu L; Lin J Eur J Med Chem; 2020 Jan; 186():111905. PubMed ID: 31785819 [TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of new 2-alkylaminoethyl-1,1-bisphosphonic acids against Trypanosoma cruzi and Toxoplasma gondii targeting farnesyl diphosphate synthase. Rosso VS; Szajnman SH; Malayil L; Galizzi M; Moreno SN; Docampo R; Rodriguez JB Bioorg Med Chem; 2011 Apr; 19(7):2211-7. PubMed ID: 21419634 [TBL] [Abstract][Full Text] [Related]
16. 3D-QSAR, molecular docking, and ONIOM studies on the structure-activity relationships and action mechanism of nitrogen-containing bisphosphonates. Liu QZ; Wang SS; Li X; Zhao XY; Li K; Lv GC; Qiu L; Lin JG Chem Biol Drug Des; 2018 Mar; 91(3):735-746. PubMed ID: 29080272 [TBL] [Abstract][Full Text] [Related]
17. Syntheses and characterization of non-bisphosphonate quinoline derivatives as new FPPS inhibitors. Liu J; Liu W; Ge H; Gao J; He Q; Su L; Xu J; Gu LQ; Huang ZS; Li D Biochim Biophys Acta; 2014 Mar; 1840(3):1051-62. PubMed ID: 24246954 [TBL] [Abstract][Full Text] [Related]
18. New insights into human farnesyl pyrophosphate synthase inhibition by second-generation bisphosphonate drugs. Fernández D; Ramis R; Ortega-Castro J; Casasnovas R; Vilanova B; Frau J J Comput Aided Mol Des; 2017 Jul; 31(7):675-688. PubMed ID: 28631130 [TBL] [Abstract][Full Text] [Related]
19. Structural characterization of substrate and inhibitor binding to farnesyl pyrophosphate synthase from Pseudomonas aeruginosa. Schmidberger JW; Schnell R; Schneider G Acta Crystallogr D Biol Crystallogr; 2015 Mar; 71(Pt 3):721-31. PubMed ID: 25760619 [TBL] [Abstract][Full Text] [Related]
20. Ternary complex structures of human farnesyl pyrophosphate synthase bound with a novel inhibitor and secondary ligands provide insights into the molecular details of the enzyme's active site closure. Park J; Lin YS; De Schutter JW; Tsantrizos YS; Berghuis AM BMC Struct Biol; 2012 Dec; 12():32. PubMed ID: 23234314 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]